[Upgrading efficiency and safety of combined antihelicobacterial treatment of ulcer patients using modern clinicopharmacological approaches].
Therapeutic monitoring of ranitidine and omeprasol using automatic analyser REMEDi HS Drug Profiling System (Bio-Rad, USA) was performed in 120 patients with morphologically verified ulcer associated with Helicobacter pylori. The addition of antibacterial drugs elevated concentration of blood ranitidine, omeprasol being stable. The highest therapeutic effectiveness was achieved with combination of ranitidine plus metronidasol and jozamycin as well as omeprasol plus metronidasol and claritromycin. Ulcer patients with concomitant hepatobiliary diseases significantly more frequently developed side effects of antihelicobacterial therapy and the rise of ranitide and omeprasol concentrations in blood can serve a prognostic criterium of their appearance. As the highest tolerance was observed in the treatment with combination ranitidine + metronidasol + oletetrin, this regimen is recommended as the safest antihelicobacterial therapy.
Bezborodnyĭ
S D
SD
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology*; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology*; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D011899:Ranitidine; D009853:Omeprazole